Американское общество гирудотерапии

Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan

Farzali S, Yaraliyeva S, Huseynov F, Manafov A, Saglam N (2025) · Turkiye Parazitolojii Dergisi · n=181

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center prospective observational cohort study of hirudotherapy across 11 clinical indications (Herba Medical Center, Baku, Azerbaijan; treatment period 2020-2024)
Sample size (n)
181
Intervention
Disposable medicinal leeches (Hirudo medicinalis) from hygienic Ministry of Ecology and Natural Resources-approved farms; treatment frequency tailored to disease severity (daily, every 3 days, or weekly)
Comparator
No randomized comparator - within-subject pre/post comparison and Pearson correlation between conditions
Primary endpoint
Treatment success rate by clinical condition, calculated based on post-treatment examinations, patient feedback, and physician evaluations
Primary result
Overall success rate 82.68 ± 29.25%; 100% success in osteoarthritis pain (n=50), lipoma (n=8), Raynaud disease (n=3), scleroderma (n=2); high success in thyroiditis (94.44%, n=18), Baker's cyst (80%, n=25), ear diseases (80%, n=10), diabetic foot ulcers (80%, n=5); moderate in eye diseases (75%, n=20); lowest in varicose veins (33.33%, n=30)
Follow-up duration
post-treatment evaluation at session completion

Key Findings

  • Largest single-center Azerbaijani cohort of hirudotherapy across 11 clinical indications (n=181, 2020-2024)
  • Highest reported success rates for osteoarthritis pain (100%, n=50) - consistent with the broader European OA RCT evidence base
  • Lowest success rate for varicose veins (33%) - contrasts with the optimistic Kalender 2014 Turkish RCT
  • Demonstrated operational feasibility of disposable leech protocol with Ministry-approved hygienic sourcing
  • Adds the post-Soviet/Caucasian geography to the international leech therapy evidence base

Limitations

  • Observational cohort with no randomized comparator - severe confounding-by-indication risk
  • Patient-reported and physician-judged 'success' lacks standardized validated outcome measures
  • Single private medical center - selection bias toward CAM-favorable patients
  • Heterogeneous indications with small per-condition samples (n=2-50)
  • No standardized adverse-event reporting protocol described

Clinical Implications

Farzali 2025 is the largest published Azerbaijani hirudotherapy cohort and provides useful real-world utilization data spanning 11 clinical indications. For ASH editorial purposes, the study is cited only as cross-cultural utilization evidence rather than as RCT-level efficacy data. The reported 100% success rate for OA pain is consistent with the European RCT body, while the low varicose-vein success (33%) is a clinically meaningful caution for that indication. The Caucasian geography fills a previously underrepresented region in the hirudotherapy literature.

Related Trials

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.